Immune responsiveness, tolerance and dsRNA: Implications for traditional paradigms

Trends in Immunology

Volumn 24, Issue 6, 2003, Pages 289-292

  Von Herrath, Matthias G ^a   Bot, Adrian ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b MannKind Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; DOUBLE STRANDED RNA; INITIATION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; PROTEIN KINASE R; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL MEMBRANE; GENE SILENCING; GENETIC CODE; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; REPLICON; REVIEW; TUMOR IMMUNITY;

EID: 0038519371     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00121-2     Document Type: Review

References (22)

1. Matzinger P. The danger model: a renewed sense of self. Science. 296:2002;301-305.
2. Medzhitov R., Janeway C.A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 296:2002;298-300.
3. Nossal G.J. Negative selection of lymphocytes. Cell. 76:1994;229-239.
4. Leitner W.W., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9:2003;33-39.
5. Schlesinger S., Dubensky T.W. Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. 10:1999;434-439.
6. Nicolson G.L., et al. Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res. 38:1978;4105-4111.
7. Herlyn D., Birebent B. Advances in cancer vaccine development. Ann. Med. 31:1999;66-78.
8. Dubensky T.W. Jr, et al. Delivery systems for gene-based vaccines. Mol. Med. 6:2000;723-732.
9. Thomis D.C., Samuel C.E. Mechanism of interferon action: autoregulation of RNA-dependent P1/eIF-2 α protein kinase (PKR) expression in transfected mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10837-10841.
10. Zhou A., et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16:1997;6355-6363.
11. Cella M., et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189:1999;821-829.
12. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology. 9:1991;1356-1361.
13. Schirrmacher V., et al. Breaking tolerance to a tumor-associated viral superantigen as a basis for graft-versus-leukemia reactivity. Int. J. Cancer. 87:2000;695-706.
14. Alexopoulou L., et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 413:2001;732-738.
15. Balachandran S., et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 13:2000;129-141.
16. Wang L., et al. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J. Clin. Invest. 110:2002;1175-1184.
17. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760.
18. Moriyama H., et al. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5539-5544.
19. Gil J., et al. Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett. 529:2002;249-255.
20. Oshiumi H., et al. TICAM-1, an adaptor molecule that participates in Toll like receptor 3 mediated interferon β induction. Nat. Immunol. 4:2003;161-167.
21. Bot A., et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167:2001;2950-2955.
22. Fire A. RNA-triggered gene silencing. Trends Genet. 15:1999;358-363.